BIOMAT Database Logo BIOMAT Database Logo

Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir. 2018

Jennifer A Fulcher, and Yushen Du, and Tian-Hao Zhang, and Ren Sun, and Raphael J Landovitz
Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles (UCLA).

Dolutegravir (DTG) is a preferred drug for initial treatment of human immunodeficiency virus type 1 infection. We present next-generation sequencing analysis of integrase genotypes during a period of virologic failure in a treatment-naive man who initiated tenofovir disoproxil fumarate/emtricitabine plus DTG.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D010078 Oxazines Six-membered heterocycles containing an oxygen and a nitrogen.
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011728 Pyridones Pyridine derivatives with one or more keto groups on the ring. Pyridinones
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006575 Heterocyclic Compounds, 3-Ring A class of heterocyclic compounds that include a three-ring fused structure. Both aromatic or non-aromatic ring structures are included in this category. Fused Heterocyclic Compounds, Three-Ring,Heterocyclic Cpds, 3 Ring,Three Ring Heterocyclic Compounds,3-Ring Heterocyclic Compounds,Fused Heterocyclic Compounds, Three Ring,Heterocyclic Compounds, 3 Ring
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human

Related Publications

Jennifer A Fulcher, and Yushen Du, and Tian-Hao Zhang, and Ren Sun, and Raphael J Landovitz
Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors.
March 2014, AIDS (London, England),
Jennifer A Fulcher, and Yushen Du, and Tian-Hao Zhang, and Ren Sun, and Raphael J Landovitz
Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression.
May 2022, The Journal of antimicrobial chemotherapy,
Jennifer A Fulcher, and Yushen Du, and Tian-Hao Zhang, and Ren Sun, and Raphael J Landovitz
Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation.
November 2020, Viruses,
Jennifer A Fulcher, and Yushen Du, and Tian-Hao Zhang, and Ren Sun, and Raphael J Landovitz
The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir.
November 2015, AIDS (London, England),
Jennifer A Fulcher, and Yushen Du, and Tian-Hao Zhang, and Ren Sun, and Raphael J Landovitz
Severe Thrombocytopenia During Dolutegravir-containing Antiretroviral Therapy.
August 2017, Internal medicine (Tokyo, Japan),
Jennifer A Fulcher, and Yushen Du, and Tian-Hao Zhang, and Ren Sun, and Raphael J Landovitz
The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir.
September 2016, AIDS (London, England),
Jennifer A Fulcher, and Yushen Du, and Tian-Hao Zhang, and Ren Sun, and Raphael J Landovitz
Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout.
August 2018, AIDS (London, England),
Jennifer A Fulcher, and Yushen Du, and Tian-Hao Zhang, and Ren Sun, and Raphael J Landovitz
Will drug resistance against dolutegravir in initial therapy ever occur?
January 2015, Frontiers in pharmacology,
Jennifer A Fulcher, and Yushen Du, and Tian-Hao Zhang, and Ren Sun, and Raphael J Landovitz
Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART.
June 2022, Infectious disease reports,
Jennifer A Fulcher, and Yushen Du, and Tian-Hao Zhang, and Ren Sun, and Raphael J Landovitz
Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients.
October 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
Copied contents to your clipboard!